Table 2.
Operative details of CRS plus HIPEC.
| n (%) | |
|---|---|
| Viscera resected | |
| Appendectomy | 4 (36.4) |
| Cholecystectomy | 7 (63.6) |
| Splenectomy | 2 (18.2) |
| Distal pancreatectomy | 1 (9.1) |
| Omentectomy | 4 (36.4) |
| Peritonectomy | 5 (45.5) |
| Anterior parietal peritonectomy | 3 (27.3) |
| Pelvic peritonectomy | 2 (18.2) |
| Urinary bladder dissection | 1 (9.1) |
| Diaphragm resection | 1 (9.1) |
| Small bowel resection | 4 (36.4) |
| Large bowel resection | 8 (72.7) |
| Low anterior resection | 1 (9.1) |
| TAH + BSO | 2 (18.2) |
| Median enteric anastomosis (range) | 1 (1–3) |
| CC | |
| CC-0 | 7 (63.6) |
| CC-1 | 4 (36.4) |
| Median PCI ± SD (range) | 14 ± 8.9 (3–29) |
| HIPEC chemotherapeutic | |
| Cisplatin plus doxorubicin | 6 (54.5) |
| Melphalan | 4 (36.4) |
| Mitomycin-c | 1 (9.1) |
| Intraoperative radiation therapy (IORT) | 5 (45.5) |
| Median operative time ± SD (range) | 8 ± 1.4 hr (6–10) |
| Median EBL ± SD (range) | 1000 mL ± 250 (700–3850) |
| Intraoperative morbidity | 0 |
| Intraoperative mortality | 0 |
SD: standard deviation; CC: cytoreduction completeness; PCI: peritoneal cancer index; HIPEC: hyperthermic intraperitoneal chemotherapy; TAH + BSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy; EBL: estimated blood loss.